4-アミノ安息香酸ブチル

Butyl 4-aminobenzoate

HCID 2482CAS 94-25-7

基本情報

標準SMILES
CCCCOC(=O)c1ccc(N)cc1
InChIKey
IUWVALYLNVXWKX-UHFFFAOYSA-N
分子式
C11H15NO2
平均分子量
193.24 g/mol
単同位体質量
193.11027872

概要

N-butyl-p-aminobenzoate is a yellow powder. Insoluble in water. (NTP, 1992)

名称と識別子

優先名称
Butyl 4-aminobenzoate
IUPAC
butyl 4-aminobenzoate
現地名
4-アミノ安息香酸ブチル
英語名
Butyl 4-aminobenzoate
分子式
C11H15NO2
分子量
193.24

名称と別名

Butyl 4-aminobenzoatebutamben94-25-7ButesineButoformButyl aminobenzoateButylcainePlanoformScuroformScuroforme4-(Butoxycarbonyl)anilineButyl keloform
名称をさらに表示
4-アミノ安息香酸ブチルブタンベンブトホルム4-アミノベンゼンカルボン酸ブチルブチルp-アミノベンゾアートブテシンブタムベンp-アミノ安息香酸ブチル4アミノ安息香酸ブチル4-アミノ安息香酸ブチル ≥98.0% (NT)4-アミノ安息香酸N-ブチル4-アミノ安息香酸n-ブチル, 99%butylaminobenzoateButesinButseinBUTOFORMEBUTAMBERO
Benzoic acid, 4-amino-, butyl esterN-Butyl p-aminobenzoatep-Aminobenzoic acid butyl ester4-Aminobenzoic acid butyl esterButyl PABADTXSID7022417NSC-128464EFW857872Q

データベース識別子

CAS
94-25-7
PubChem CID
2482
DTXSID
DTXSID7022417
ChEMBL
CHEMBL127516
ChEBI
CHEBI:3231
UNII
EFW857872Q
EC Number
202-317-1
Nikkaji
J4.698A

物性

構造計算による物性

XLogP
2.9
極性表面積
52.3 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
5
重原子数
14

実験および物理化学的性質

Chemical ClassesOther Uses -> Sunscreens
DrugsPharmaceuticals -> Listed in ZINC15
SpringerMaterials PropertiesFusion temperature
LogP · 2 件

log Kow= 2.87

3.05

OdorOdorless
TasteTasteless

物理化学的性質

融点
57 · 57-58 °C(lit.)
沸点
174 °C8 · 174 °C8 mm Hg(lit.)
比重(密度)
1.0945 · 1.0945 (rough estimate)
屈折率
1.548 · 1.5480 (estimate)
貯蔵温度
Keep in dark place,Inert atmosphere,Room temperature
溶解性
クロロホルム(微量)、メタノール(微量)

化学的性質

化学的特性It is a solid at room temperature, with a melting point of 58°C and a boiling point of 173.4°C (at 8mmHg). Butyl p-aminobenzoate is insoluble in water.

安全と法規制

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 43 reports by companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationBenzoic acid, 4-amino-, butyl ester: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Other Safety InformationIMAP assessments - Benzoic acid, 4-amino-, butyl ester: Human health tier I assessment
Fire HazardsFlash point data for this chemical are not available. It is probably combustible. (NTP, 1992)
Fire PotentialCombustible when exposed to heat or flame.
Health HazardsSYMPTOMS: Symptoms of exposure to this compound may include sensitivity dermatitis, nausea, vomiting and methemoglobinemia.
Hazards SummaryMay cause tissue necrosis after injection, possible due to precipitation of crystals; [HSDB] May cause methemoglobinemia and skin sensitization; [CAMEO] An irritant; May cause skin sensitization; [MSDSonline]

安全と保護具

Fire FightingA fire in your laboratory involving this chemical should be extinguished with a dry chemical, carbon dioxide or halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: Should a spill occur while you are handling this chemical, you should dampen the solid spill material with alcohol, then transfer the dampened material to a suitable container. Use absorbent paper dampened with alcohol to pick up any remaining material. Seal the absorbent paper, and any of your clothes, which may be contaminated, in a vapor-tight plastic bag for eventual disposal. Solvent wash all contaminated surfaces with alcohol followed by washing with a strong soap and water solution. Do not reenter the contaminate area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Interactions · 2 件

These agents /cholinesterase inhibitors such as antimyasthenics; cyclophosphamide; demecarium; echothiophate; neurotoxic insecticides, possibly including large quantities of topical malathion; isoflurophate; thiotepa/ may inhibit metabolism of ester derivatives; absorption of significant quantities of ester derivatives in patients receiving a cholinesterase inhibitor may lead to increased risk of toxicity. /Topical anesthetics/

Metabolites of PABA-derivative topical anesthetics may antagonize antibacterial activity of sulfonamides, especially if the anesthetics are absorbed in significant quantities over prolonged periods of time. /Topical anesthetics/

Adverse EffectsMethemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect
Non-Human Toxicity Excerpts...IN EPIDURAL MIXT...BEEN INCRIMINATED AS POTENTIAL CAUSE OF TISSUE NECROSIS & NEURITIS, POSSIBLY DUE TO CRYSTAL PRECIPITATION (DEPOT EFFECT).
Non-Human Toxicity ValuesLD50 Mouse ip 67 mg/kg

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
3
tsca
TSCA listed
rtecs
DG1530000
hs_code
29224995
risk_code
36/37/38-43
化審法
(3)-1443

化学と産業

薬理情報

Protein BindingAs all other local anesthetics, it is thought that butamben will be highly bound to plasma proteins, mainly to alpha-1-acid glycoprotein.
Pharmacodynamics · 1 件

Butamben has been shown to selectively inhibit dorsal root pain signal transmission for periods of months when administered as epidural suspensions. The effect of butamben is not related to any significant loss of motor function which indicates that it targets specifically the pain-sensing C fibers of the dorsal root. When administered topically, butamben produced anesthesia by accumulating in the nerve cell membrane causing it to expand and lose its ability to depolarize and blocking the impulse transmission.

Mechanism of Action · 2 件

Butamben acts by inhibiting the voltage-gated calcium channels in dorsal root ganglion neurons. The modification in this channels is thought to cause a disturbance of the channel kinetics acceleration. It is reported as well that butamben is an inhibitor of the sodium channels and a delayed rectifier of potassium currents. All the effects of butamben are performed in the root ganglion neurons which suggests that the related anesthetic effect may be caused by the reduced electrical excitability.

...ACTION IS TO INTERFERE WITH INITIATION & TRANSMISSION OF NERVE IMPULSE. PRESENT THEORY HOLDS THAT LOCAL ANESTHETICS PREVENT DEPOLARIZATION OF NERVE MEMBRANE &, HENCE, PROPAGATION OF IMPULSE. ...THOUGHT TO BE DUE TO INTERFERENCE WITH MUTUAL EXCHANGE OF SODIUM & POTASSIUM IONS ACROSS MEMBRANE. /LOCAL ANESTHETICS/

Biological Half-LifeThe effective half-life of unencapsulated butamben is registered to be of 90 minutes. Some efforts were made to prepare D, L-lactic acid capsules which increased the half-life of butamben to even 400 hours.
Metabolism/MetabolitesThe metabolic pathway of butamben follows the same pattern of other local anesthetics and it is driven mainly by the hydrolysis via cholinesterase for the formation of inert metabolites.
MeSH Pharmacological Classification · 1 件

Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.

用途と製造

Uses · 3 件

Used as a local anesthetic and in burn treatment ointments and suntan preparations; [Hawley] Used essentially 100% as a local anesthetic; [HSDB]

MEDICATION

MEDICATION (VET)

U.S. Exports · 2 件

(1977) No Data

(1979) No Data

U.S. Imports · 2 件

(1977) No Data

(1979) No Data

U.S. Production · 2 件

(1978) GREATER THAN 1.36X10+6 G (INCL PICRATE)

(1979) GREATER THAN 1.36X10+6 G (INCL PICRATE)

Consumption PatternsESSENTIALLY 100% AS AN ANESTHETIC
Methods of Manufacturing · 4 件

ESTERIFICATION OF P-NITROBENZOIC ACID WITH N-BUTYL ALCOHOL FOLLOWED BY REDUCTION WITH IRON FILINGS AND HYDROCHLORIC ACID

PREPARED BY ESTERIFYING P-NITROBENZOIC ACID WITH N-BUTYL ALCOHOL & REDUCING NITRO GROUP TO AMINO GROUP WITH IRON FILINGS & HCL.

Prepn: Brill, J. Am. Chem. Soic. 43, 1322 (1921); Adams, Volwiler, U.S. pat 1,440,652 (1923 to Abbott); Brit. pat. 252,870; C.A. 17, 1243 (1923); C.A. 21, 2478 (1927).

Produced by the esterification of 4-nitrobenzoyl chloride with n-butanol and reduction of the resulting nitroester.

応用分野 · 3 件

用途有機合成原料、医薬品原料。

使用n-Butyl 4-aminobenzoate is used as pharmaceutical intermediate.

一般的な説明Yellow powder. Insoluble in water.

調製方法

Butyl p-aminobenzoate is manufactured via esterification of p-nitrobenzoic acid with n-butyl alcohol, followed by the reduction of the nitro group to an amino group.

純化方法Crystallise Butamben from EtOH. [Beilstein 14 IV 1130.]

サプライヤー50 社

国药集团化学试剂有限公司86-21-63210123 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
Shandong chuangyingchemical Co., Ltd.18853181302 · [email protected]
南通润丰石油化工有限公司66017690 19952660367 · [email protected]
補足説明 · 1 件

定義ChEBI: An amino acid ester resulting from the formal condensation of the carboxy group of 4-aminobenzoic acid with the hydroxy group of butan-1-ol. Its local anaesthetic properties have been used for surface anaesthesia of the skin and mucous membranes, and for r lief of pain and itching associated with some anorectal disorders.

関連反応

11 件

関連ノート

読み込み中…